SIGA Stock — SIGA Technologies Inc.: Cash, EV, Pipeline

Share price

$3.14

Market cap

$225.6M

Cash

$117.6M

Enterprise value

$108.0M

Balance sheet

Cash	$117.6M
Debt	$0.0M
Net cash	$117.6M
Enterprise value	$108.0M
Basic shares	71.8M shares
Fully diluted shares	71.8M shares
Fully diluted market cap	$225.6M
Cash per share	$1.64

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading SIGA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 12 - Mar 26	Tecovirimat	Phase 2	Smallpox	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

TPOXX

Approved · Active Modality: Oral capsule / intravenous formulation

Aliases tecovirimat, Tecovirimat-SIGA

Partnerships BARDA (19C contract for oral and IV TPOXX courses). Hikma MENA FZE (Mar 2026): exclusive license and distribution agreement to register and commercialize oral TPOXX in the Middle East and North Africa; SIGA remains sole manufacturer

Indications

Smallpox (oral TPOXX; IV TPOXX approved May 18, 2022) (Approved)
Smallpox post-exposure prophylaxis (oral TPOXX) (Stage not disclosed)

Catalysts

— 2027 (1H)

Status note Oral TPOXX approved by FDA for smallpox (Jul 2018); by EMA/MHRA (as Tecovirimat-SIGA) for smallpox, cowpox and vaccinia complications; by PMDA for smallpox, mpox, cowpox and vaccinia complications; by Health Canada for smallpox. Mar 2026 CHMP confirmed positive benefit-risk for smallpox/cowpox/vaccinia complications but recommended against mpox use (EC adopted May 2026).

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Tecovirimat
Lead indication	Smallpox
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04957485	Phase 2	Active, not recruiting	Sponsor	SIGA Technologies	—	Smallpox	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for SIGA Technologies on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

SIGA — SIGA Technologies Inc.